ADVISORY, May 17, 2007 (PRIME NEWSWIRE) --
What: Michel de Rosen, President & CEO of ViroPharma Incorporated (VPHM) will preside over the opening bell. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Friday, May 18, 2007 at 9:30 a.m. ET Contacts: Will Roberts, Senior Director, Corporate Communications +1-610-321-6288; Will.Roberts@ViroPharma.Com NASDAQ MarketSite: Jolene Libretto; 646.441.5220; mobile - 347.219.9539 Jolene.Libretto@NASDAQ.com
The opening bell is available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Jolene Libretto at (646) 441-5220.
An audio transmission of the opening bell is also available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Waterfront fiber 1623 as well.
A live webcast of the NASDAQ Opening Bell will be available at: http://www.nasdaq.com/reference/marketsite_about.stm.
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About ViroPharma Incorporated (VPHM):
ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(r) approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/Vancocin_pi_2007.htm). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the Company's website at www.viropharma.com.